论文部分内容阅读
随着现代诊疗技术的提高,大剂量化疗和靶向药物的应用,淋巴瘤的生存期延长;同时反复化疗后继发的治疗相关性急性髓系白血病(AML)/骨髓增生异常综合征(MDS)发生率也不断上升,并成为非霍奇金淋巴瘤(NHL)预后不良的远期并发症之一。本院最近诊治了1例弥漫大B细胞淋巴瘤(DLBCL)化疗后18个月继发急性早幼粒细胞白血病(APL)的患者,现对此进行报道,并复习文献,以
With the improvement of modern diagnosis and treatment techniques, the application of high-dose chemotherapy and targeted drugs prolongs the survival of lymphoma; meanwhile, the treatment-related acute myeloid leukemia (AML) / myelodysplastic syndrome (MDS) The incidence is also rising and has become one of the long-term complications of poor prognosis in non-Hodgkin’s lymphoma (NHL). We recently reported the diagnosis and treatment of one patient with acute promyelocytic leukemia (APL) 18 months after chemotherapy with diffuse large B-cell lymphoma (DLBCL) and reviewed the literature to